Confident Transitions: Introducing myLoop powered by CamAPS FX for Pregnancy Care

“Switching to myLoop is like driving a new car—if you already know how to drive, it takes little time to adapt. Learning is quick and intuitive.” – Prof. Beato-Vibora

The “Confident Transitions: Introducing myLoop powered by CamAPS FX for Pregnancy Care” webinar with Prof. Beato-Vibora and Núria Alonso-Carril explored how myLoop powered by CamAPS FX, enhances diabetes management during pregnancy.

Watch the full Webinar here!

Take home messages

• Transitioning between AID systems, when personalized to the user’s needs, can enhance both glycemic outcomes and user satisfaction without compromising glycemic stability.¹

• Make sure to give a structured education to your patient who is transitioning from another AID or MDI to myLoop.

• Switching from another AID or from MDI to myLoop has been shown to reduce glucose variability, minimize interventions, and enhance overall glucose management.¹

• There is no definitive stage in pregnancy where it becomes too late to switch to myLoop.

• The recommended glycemic target for myLoop during labor and delivery should remain as last programmed, utilising "Ease-off" and "Boost" to fine-tune insulin delivery as needed.

• Postpartum, it is advised to adjust target glucose levels and restore the initial basal rate following the Manual Mode Adjustment Protocol, while resetting the ICR to pre-pregnancy levels.

The session was designed to provide healthcare professionals with insights to cases where the advanced technology of myLoop was used and showed improved glucose management throughout pregnancy.

Prof. Beato-Vibora introduced myLoop with it’s adaptive learning algorithm CamAPS FX and the key features "Ease-off" and "Boost" for best personalized diabetes management. She also highlighted the flexibility in sensor choice, allowing users to select either Dexcom G6 or Abbott FreeStyle Libre sensors.²

For pregnant women with T1D, the system allows to set personal glucose targets and to make adjustments throughout pregnancy. It is important to regularly review and adapt the insulin to carb ratio, and update the entered body weight. Women must return to their pre-pregnancy insulin settings either before delivery in the case of a C-section or immediately after delivery following a vaginal birth to prevent severe hypoglycemia due to the postnatal change in insulin sensitivity.³

Real-world cases of pregnant women using or switching to myLoop were presented in this webinar, exemplifying the clinical experience of Prof. Beato-Vibora and colleagues. Two of the presented cases were participants of their recently published study.¹ In the study they tracked 96 individuals with T1D who had switched from a previous AID to another commercial AID system, with 55 moving to CamAPS FX. Pregnancy (n=10) and pregnancy planning (n=24) motivated 34 participants (35% of switches) to change to another AID system- 33 of them switched to CamAPS FX, primarily because myLoop powered by CamAPS FX is the only commercially available AID system indicated for pregnant women with type 1 diabetes.⁴

Now, let us explore the 2 cases of pregnant women, along with one case of a woman preparing for pregnancy, as presented by Prof. Beato-Víbora and Núria Alonso-Carril during this webinar.

Case 1: Switching from AID to myLoop

A 29-year-old woman, previously using the Advanced Hybrid Closed Loop (AHCL) system that was available at that time, experienced complications during her first pregnancy , including preeclampsia, preterm birth, and a C-section due to fetal distress.

During her second unplanned pregnancy, following a consultation with her diabetes team, she was switched to myLoop at 10 weeks of gestation with an HbA1c of 7.2% and a Time in Rang in pregnancy (TIRp) of 53%. The system was chosen due to her prior complications, the fact that her glucose levels were not consistently within the target range, and the additional control features it offers. Personalized settings were done, as recommended by the diabetes team including lower personal glucose targets, modified insulin-to-carbohydrate ratios for each trimester, and updated body weight entry every few weeks.

Her TIRp improved to 76% by the third trimester with a very flat glucose profile, and HbA1c dropped to 6.0%. Auto mode remained active throughout , with system control via phone.

“Switching AID systems isn’t difficult for these women because they are experts in diabetes management. They already understand pumps, sensors, and algorithms. The key is explaining the differences.”

Case 2: Transition from another AID to myLoop

A 36 years old , diagnosed with T1D with the age of 9 and a medical history with dyslipidemia and a chronic thyroid condition consistent with thyroiditis. She was under medical supervision due to a desire for pregnancy without contraception, as well as for the management of chronic diabetes-related complications. A graph illustrating the progression of her metabolic control, as reflected by glycated hemoglobin (HbA1c) levels, showed a value of 7.1% which is considered suboptimal for the initiation of pregnancy. She was previously on sensor-augmented pump (SAP) therapy and changed to AHCL system in 2021, but continued to struggle with diabetes management. Her time in range was 48% with a mean glucose of 8.3 mmol/L, a standard deviation of 2.9 mmol/L, a glucose management indicator (GMI) of 6.9%, and a glycemic variability of nearly 36%. Due to these facts, the diabetes team decided to switch her to myLoop to improve glycemic management and achieve pre-pregnancy-specific targets. Adjustments were made during a single training session with a technical consultant present, as she was already an experienced HCL-user. The settings remained the same as in the previous system and a Personal Glucose Target (PGT) was set at 5.6 mmol/L.

One week after initiation, she experienced lower glucose variability, reduced interventions, and improved glucose management. Her TIR increased to 65%, and her Glucose Management Indicator (GMI) reached 6.4%, aligning with an HbA1c which is suitable for pregnancy.

Transitioning from another AID to myLoop powered by CamAPS FX, helped this woman to improve her glucose management, with less effort and to achieve the recommended pre-gestational HbA1c target.

Case 3: Switching from MDI to my Loop during pregnancy

A 35-year-old woman with T1D and a with intrapartum caesarean section for suspected fetal distress and neonatal hypoglycemia, faced high glucose variability (52.6%) and 39% Time Above Range (TAR) at 6.6 weeks pregnant. Despite elevated glucose levels, she struggled with insulin titration and meal planning.

By week 21, while glucose management improved, variability remained high due to inconsistent carb counting and treatment adjustments. To enhance stability, myLoop was initiated, with a structured four-session onboarding process, as she was transitioning from MDI. Follow-ups occurred biweekly.

Within a week, her pregnancy specific TIR rose to 68%, maintained stable at 70% with reduced glucose variability (<36%) throughout pregnancy. At 37 weeks, she underwent a planned C-section in the morning with a fasted blood glucose level of was started and proactively used during fasting.

Following a previous pregnancy with complications, the switch from MDI to myLoop in gestational week 21 improved glycemic parameters in the subsequent pregnancy, that terminated with the delivery of a healthy baby (2,460g) without complications, with immediate initiation of breastfeeding.

Based on Prof. Beato-Víbora’s experience, these are the adjustments she recommends for using myLoop during pregnancy, labor and delivery, and the postpartum period:

During Pregnancy:

• Adjust basal rate every 4 weeks (manual mode).

• Update weight every 2-4 weeks if needed.

• Adapt ICR based on post-prandial readings.

During Labour & Delivery:

• Monitor blood glucose hourly (blood tests if needed).

• Use "Ease-off" proactively during fasting.

• Activate "Boost" if hyperglycemia persists for more than an hour.

After Birth:

• Adjust target glucose levels.

• Double insulin-to-carb ratios.

• Set active insulin time to 3 hours (manual mode).

• Revert to initial basal rate following the Basal Adjustment Protocol (manual mode).

Watch the full Webinar here!